At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiasthmatics; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 06 Dec 2000 Profile reviewed but no significant changes made
- 24 Jun 1998 No-Development-Reported for Asthma in United Kingdom (PO)
- 31 Dec 1994 Preclinical development for Asthma in United Kingdom (PO)